Physician profile
Philip M Smith
NPI 1952351876
$17,502.77
in general payments reported to CMS, 2019-2025
34 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,438 · 2020: $3,720 · 2021: $1,041 · 2022: $1,718 · 2023: $3,049 · 2024: $2,725 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,902 · Consulting Fee: $645 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,901.62 |
| Consulting Fee | $645.00 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $9,551.19 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Glaukos Corporation | $2,404.42 | 2019-2025 | Idosetr, Idose, Istent Inject Trabecular Micro-Bypass System |
| Sight Sciences, INC. | $830.54 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $635.32 | 2022-2025 | Durysta |
| Rxsight INC | $479.70 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $456.40 | 2019-2020 | |
| Biotissue Holdings INC. | $368.04 | 2020-2023 | |
| Alcon Research LLC | $350.00 | 2019 | |
| Ivantis, INC | $303.64 | 2019-2020 | |
| Beaver-Visitec International, INC. | $240.20 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $232.93 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $212.81 | 2019-2020 | |
| Dompe US, INC. | $197.06 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $171.81 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Carl Zeiss Meditec USA, INC. | $164.83 | 2023 | Artevo 800 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $91.80 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $90.34 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Xiidra |
| Apellis Pharmaceuticals, INC. | $84.09 | 2024-2025 | Syfovre |
| Ocular Therapeutix, INC. | $84.03 | 2024-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $80.94 | 2019-2025 | |
| Allergan, INC. | $64.14 | 2019-2020 | |
| Omeros Corporation | $61.56 | 2019 | |
| Kala Pharmaceuticals, INC. | $54.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $50.44 | 2024-2025 | Eylea Hd |
| Genentech USA, INC. | $46.80 | 2022 | |
| New World Medical,INC. | $29.96 | 2019-2022 | |
| The Cameron-Ehlen Group, INC. | $28.63 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $21.67 | 2025 | Xdemvy |
| Akorn, INC. | $21.43 | 2020 | |
| Thea Pharma INC. | $19.88 | 2024 | Iyuzeh |
| Amgen INC. | $19.79 | 2025 | Tepezza |
| Shire North American Group INC | $18.75 | 2019 | |
| Harrow Eye, LLC | $18.42 | 2025 | Iheezo |
| Mallinckrodt Hospital Products INC. | $16.24 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.